FDA optimistic about Pfizer drugs to treat breast cancer palbociclib
April 11, 2013 Pfizer, the FDA new drug developed to treat breast cancer palbociclib (PD-0332991) high hopes. The FDA reviewed the interim results of the drug after that this may be a breakthrough cancer drug. Palbociclib as the most important one three Pfizer study drug is an oral cyclin-dependent kinase inhibitor 4,6. Last year, Pfizer has five drugs received FDA clearance to market, while the company also carried out on the existing research institutions drastically streamlining and cancer drug development as the company's main research directions.
FDA optimistic about Pfizer drugs to treat breast cancer palbociclib
ReplyDeleteApril 11, 2013 Pfizer, the FDA new drug developed to treat breast cancer palbociclib (PD-0332991) high hopes. The FDA reviewed the interim results of the drug after that this may be a breakthrough cancer drug.
Palbociclib as the most important one three Pfizer study drug is an oral cyclin-dependent kinase inhibitor 4,6.
Last year, Pfizer has five drugs received FDA clearance to market, while the company also carried out on the existing research institutions drastically streamlining and cancer drug development as the company's main research directions.
Medchemexpress Can provide the above product,its website:www.medchemexpress.com
U0126
AS703026
BIX02188
BIX02189
AZD8330
PD318088
BMS 777607
MEK inhibitor
GDC-0973
CI-1040